Full-Time

Senior Director

Quality

Tr1X

Tr1X

11-50 employees

Develops cellular immunotherapies for autoimmune diseases

Compensation Overview

$240k - $270k/yr

+ Discretionary annual target bonus + Incentive stock options

San Diego, CA, USA

In Person

Position is on-site in San Diego, California.

Bachelor of Science (BS)

Category
Biology & Biotech (1)
Required Skills
Microsoft Office
FDA Regulations
Word/Pages/Docs
Risk Management
Excel/Numbers/Sheets
PowerPoint/Keynote/Slides

Get referred to Tr1X

See people who can refer or advise you

Requirements
  • A Bachelor of Science degree in a scientific discipline, including pharmaceutical, biologics, or a related field.
  • A minimum of 12 years of related experience in the pharmaceutical or biotechnology industry at FDA-regulated manufacturing sites within quality operations.
  • A minimum of 5 years of leadership or management experience within quality, including at least 3 years of direct supervisory experience of technical or quality professionals.
  • Background in biologics or cellular therapy manufacturing.
  • Experience hosting regulatory agency inspections and presenting product and quality compliance programs successfully to regulatory agency reviewers.
  • Advanced knowledge of FDA and International Council for Harmonisation regulations, Good Practice quality systems, and operational excellence required for manufacturing cellular therapeutic products.
  • General working knowledge of Good Clinical Practice and clinical quality assurance.
  • Demonstrated ability to perform long-term project planning with meaningful timelines and budget forecasting.
  • Ability to prioritize multiple tasks, work under timeline pressures, and drive tasks to completion.
  • Effective verbal and written communication and solid time management and organizational skills.
  • Proficiency with Microsoft Office suite software, including Word, Excel, and PowerPoint.
  • Legally authorized to work for any employer in the United States.
Responsibilities
  • Provide oversight of quality risks and report risks to senior stakeholders.
  • Manage a global audit program to ensure vendor and supplier performance and compliance, including developing and presenting meaningful metrics and summaries.
  • Oversee maintenance of the quality management system that collects, stores, establishes control, and provides governance for the use of Good Practice data.
  • Ensure compliance with regulatory requirements and industry standards, including FDA, EMA, and ICH guidelines.
  • Provide strategic direction and guidance to the quality team, ensuring alignment with company objectives and goals.
  • Drive continuous improvement initiatives to enhance the efficiency and effectiveness of quality processes and systems.
  • Represent the company in interactions and maintain relationships with regulatory agencies, external partners, industry groups, and internal stakeholders.
  • Partner with clinical operations, contract research organizations, and other key clinical staff to ensure clinical trials are conducted according to Good Clinical Practice guidelines.
  • Monitor and assess quality metrics and key performance indicators to identify trends and areas for improvement.
  • Collaborate with cross-functional teams to integrate quality considerations into product development, manufacturing, distribution, and clinical study design and execution.
  • Conduct regular audits and inspections to assess compliance and identify potential risks and areas for improvement.
  • Foster a culture of quality and compliance throughout the organization through training, communication, and recognition programs.
  • Stay current with industry trends and developments and recommend new technologies and approaches to enhance quality operations.
  • Lead and mentor a team of quality professionals, providing guidance, feedback, and development opportunities.
  • Perform other responsibilities as required by business needs.

Tr1X focuses on cellular immunotherapies for autoimmune and inflammatory diseases. Using a proprietary platform, it creates first-in-class cell therapy products that aim to rebalance the immune system and restore homeostasis, achieving long-term tolerance. The company develops and commercializes these therapies, generating revenue through partnerships, licensing, and direct sales, with a business base in La Jolla, CA. How it works: the core product is a cell therapy designed to modulate immune responses so the body reaches stable immune balance rather than ongoing suppression. This differs from many competitors by emphasizing durable immune tolerance via a proprietary platform and by pursuing partnerships and licensing to bring therapies to healthcare providers and patients. The goal is to deliver durable immune tolerance for autoimmune and inflammatory diseases through first-in-class cell therapies.

Company Size

11-50

Company Stage

Early VC

Total Funding

$125M

Headquarters

San Diego, California

Founded

2018

Get referred to Tr1X

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • CIRM approved $8 million for TRX319 in June 2026, supporting execution.
  • October 2025 financing extended runway into 2027, reducing near-term fundraising pressure.
  • ASGCT 2026 presentations kept Tr1X visible among autoimmune cell-therapy investors.

What critics are saying

  • TRX103 still lacks efficacy proof beyond small Phase 1 cohorts in 2026.
  • TRX319's 39-patient trial runs through 2029, delaying commercialization and de-risking.
  • If TRX103 and TRX319 fail, Tr1X has no approved products or revenue.

What makes Tr1X unique

  • Tr1X pairs allogeneic Tr1 cells with CAR-Tr1 engineering, unlike autologous competitors.
  • TRX103 produced early safety, persistence, and immune-reconstitution signals in 2026 HSCT patients.
  • TRX319 targets progressive multiple sclerosis with a first-in-class off-the-shelf CAR-Tr1 approach.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

Health Savings Account/Flexible Spending Account

Unlimited Paid Time Off

401(k) Company Match

Flexible Work Hours

Stock Options

Performance Bonus

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

-2%

2 year growth

-2%
San Diego Business Journal
Oct 27th, 2025
Tr1X Bio Secures $50M Funding

Tr1X Bio, based in San Diego, received FDA approval for IND status for TRX319, aimed at treating progressive multiple sclerosis. The company secured $50M in financing to support clinical trials for TRX319, set to begin next year. Tr1X's technology, based on research by Dr. Maria Grazia Roncarolo, uses allogeneic cells to treat autoimmune diseases. The company also advances TRX103 for graft vs. host disease and Crohn's disease, backed by an $8M CIRM grant.

GlobeNewswire
Oct 14th, 2025
Tr1X Announces FDA Clearance of IND Application for TRX319, a First-in-Class Allogeneic CAR-Tr1 Treg Cell Therapy for Progressive Multiple Sclerosis, and $50 Million in Additional Financing

Tr1X announced the FDA has cleared its IND application for TRX319 in progressive multiple sclerosis and a $50M financing that extends its runway into...

Clinical Trial Vanguard
Apr 7th, 2025
TR1X Awarded $8M Grant for TRX103 GvHD Trial

TR1X awarded $8M grant for TRX103 GvHD trial.

Benzinga
Apr 4th, 2025
Tr1X Awarded $8 Million Cirm Grant To Support Trx103 Phase 1/2A Clinical Trial For Graft-Versus-Host Disease

SAN DIEGO, April 04, 2025 (GLOBE NEWSWIRE) -- Tr1X, Inc. (pronounced "Trix"), a clinical-stage biopharmaceutical company developing first-in-class allogeneic engineered Treg and CAR-Treg cell therapies with the potential to cure autoimmune and inflammatory diseases, today announced that the California Institute for Regenerative Medicine (CIRM) has awarded the Company an $8 million grant to support its ongoing Phase 1/2a clinical trial of TRX103, an engineered Tr1 Treg cell therapy for use in the prevention of graft-versus-host disease (GvHD) in blood cancer patients undergoing mismatched stem cell transplants. This award follows a $4 million CIRM grant received by Tr1X in early 2024 for late-stage preclinical research that helped to advance TRX103 to human trials. The TRX103 Phase 1/2a clinical trial is being led by Maria Grazia Roncarolo, MD, co-founder, president and head of RD at Tr1X, with patients enrolling at leading stem cell transplant centers across the country. The trial is designed to treat patients receiving a mismatched or haploidentical transplant with a one-time infusion of TRX103. The Company has reported positive initial persistence and safety data in the first two patient cohorts, with additional data anticipated to be reported in 2025

TMCnet
Apr 4th, 2025
Tr1X Awarded $8 Million CIRM Grant to Support TRX103 Phase 1/2a Clinical Trial for Graft-Versus-Host Disease

Tr1X is developing TRX103 for the treatment of several immune and inflammatory disorders.